Brief Items of Interest, March 2016

Hair loss news first:

Since the last “brief items of interest” post a month ago, there have been numerous important developments in the hair loss world. Some involve renowned researchers that have already been covered a few times on this blog before.

— Meiji Seika Pharma (Japan) and Dr. Takashi Tsuji, head of the Laboratory for Organ Regeneration at the Riken Center for Developmental Biology (Japan), have entered into an important partnership.  Their goal is “to develop treatments to regrow lost hair.”  Apparently 12 million adult men in Japan suffer from hair loss. The partnership will focus on regenerative medicine rather than on any kind of drug development.  Japan’s new laws will also help speed up clinical trials in the regenerative medicine sector.

— Also in Japan, a new article on Shiseido mostly covers things we already know and confirms that they will start trials this year. However, the ending is of interest: “The fee to receive the treatment will be at least 100,000 yen ($887).”  A lot cheaper than I expected.

— I have covered Dr. Colin Jahoda and his 3D spheroid culturing of dermal papilla cells on this blog before.  Mr. Jahoda has been a legend in the hair loss research world since the 1980s, but it seems like he may have reached the end of his best years in terms of research.  Thankfully, the Chinese are continuing from where he left off.  A team from Southern Medical University (China) and Dr. Malcolm Xing from Canada have published an interesting update on their work with 3D spheroids.  It seems like they have improved somewhat on Dr. Jahoda’s work with a novel hanging-drop method. I am glad that they are continuing this area of crucial research.  Note that Dr. Xing gave Dr. Jahoda a good deal of credit when I interviewed the former.

— Another renowned researcher that I have covered before, Dr. Elaine Fuchs, just published an important article summarizing how stem cells get activated to produce new hair.  Forkhead box C1 (FOXC1) is a key transcriptional regulator of hair follicle stem cell activity and bulge maintenance.  Also see another summary of the same study.  One of the interesting conclusions of the article seems to imply that premature hair loss is also correlated with premature hair greying.  Something I have noticed in many people.  “Hair follicle stem cells influence the behavior of melanocyte stem cells, which co-inhabit the bulge niche,” explains Fuchs. “Thus, when the numbers of hair follicle stem cells declined with age, so too did the numbers of melanocyte stem cells, resulting in premature greying of whatever hairs were left.”

— Tiny Singapore might have a stagnant and small population, but they still care about hair loss.  Their scientists (plus others from Stanford) recently published a paper covering the gene Axin2 and autocrine Wnt/β-catenin signaling.  Complicated stuff to understand for a non-scientist such as myself.

A new cream based hair loss treatment from Yeditepe University called Kelopesia was just announced out of the blue. Their presentation is amateurish, and as soon as I hear the words “stem cells” along with “hair” these days my scam radar turns on unless the company or institution has been involved in the hair loss research field for many years.  Anyway, these guys are using foreskins for this treatment. Product will supposedly be released in a month.  If it was not a university, I would say a 100 percent certainty this is a scam.  I still feel that this is going to be a major disappointment.

Follicum press release:  successful Phase 1 safety trials.

— Antonio Conte’s hair transplant seems to have turned out to be pretty good.

Christopher1’s experience with Kerastem thread worth following. Under my last post someone posted a comment that the treatment did not work and costs a lot.

— At least once a year, we in the US get to read a story about a major Rogaine theft.  Invariably, the thief is bald and this is emphasized by the media.  I suspect all of these bald Rogaine thieves are selling most of the stolen cans rather than using their contents on their own scalps.

And now on to medical items of interest:

I will shorten this section for this month since the hair loss one was so lengthy.

— An interesting recent video interview/discussion with Dr. Aubrey de Grey, Dr. Bil Andrews and Elizabeth (Liz) Parrish (all three of whom I have covered on this blog before):

— Another recent one with just Dr. Bill Andrews:

— And another recent one with just Liz Parrish:

How long until we can print human faces in the lab?

199 thoughts on “Brief Items of Interest, March 2016”

    1. No he did not but when there is no news, what do you want him to say ? Plus he has something else to think about, he has family and friends!

  1. Is anyone trying out that Rice Bran Extract? Was thinking about starting Minoxidil, but the extract seems like a better alternative?

    1. I ordered some yesterday. Any advise on how to use 3% of it on the scalp? 3 drops of rice bran and 97 drops on a different oil and mix?

  2. i had erectile disfunction for 6 days straight on finesteride.. it was the darkest week of my life. i almost cried when it came back lol seriously me and my girlfriend took a picture hahahahaha

    1. I had the same experience, Egghead. It really made me view hairloss a little differently. It made me realize things could be worse. lol

  3. this is good, but, I wouldn’t overstate that this is a “big” pharma company. Just for a little reference, VRX-Valeant has tanked since Oct. and some question what the equity is actually worth if anything…but its market cap is still over $9.5 Billion USD, and this comapany that took over Vixen has a market cap of roughly $300 million, which falls into the kinda very micro cap almost (under $1 billion is small)…anyways this is good considering Histogen can barely raise anything for their $25 Million bond issue…which is pathetic in the capital markets…anyways HOPEFULLY Christano stays on as a researcher!!!! That’s worth the most in my opinion. Money backing her up. That’s all.

    1. never mind really…this is mainly a company who only previously had two drugs or something in the pipeline. If this works and is safe, this stock could likely go up 5 fold from here easily lol. We’ll see.

Leave a Reply

Your email address will not be published. Required fields are marked *